Health

111, Inc. Achieves Full Distribution Coverage Across Mainland China with the Opening of Two Key Fulfillment Centers

SHANGHAI, March 16, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (Nasdaq: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, announced today it has opened two new state-of-the-art, technology...

2021-03-16 17:40 3081

Microba Life Sciences partners with Unilever to target sleep through the gut microbiome

BRISBANE, Australia, March 15, 2021 /PRNewswire/ -- Experts in gut microbiome analysis, Microba Life Sciences , is empowering global consumer goods companyUnilever  to take a novel approach to this problem by exploring the links between sleep...

2021-03-15 21:59 3359

Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal

HONG KONG, March 15, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-bindin...

2021-03-15 19:00 3449

Thinklabs Announces Medical Device Single Audit Program (MDSAP) Certification and TGA Approval in Australia

Thinklabs is opening business to Australian territories, inclusive of hospitals, private practices, and medical facilities. CANBERRA, Australia, March 9, 2021 /PRNewswire/ -- Thinklabs, manufacturer of Thinklabs One, the smallest, most powerful electronic stethoscope in the world, today ann...

2021-03-12 23:06 4877

Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines

SHANGHAI, March 11, 2021 /PRNewswire/ -- Delonix Bioworks Ltd. (Delonix), a biotechnology company dedicated to developing the next generation vaccines with synthetic biology approaches, has recently closed a$14 million Series Seed financing led by Boehringer Ingelheim Venture Fund (BIVF) and IDG ...

2021-03-11 21:21 1907

PharmAbcine to Present at AACR Annual Meeting 2021

DAEJEON, South Korea, March 11, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today an e-posterpresentation featuring nonclinical data of PMC-309 at American Association for Cancer Researc...

2021-03-11 21:00 1803

Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients

SUZHOU, China, March 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalut...

2021-03-11 14:54 5117

First pocket inhaler for Covid-19 and other viral mutations: DG-Nika AG - a new approach to therapy & proactive protection from the pandemic

BUOCHS, Switzerland, March 11, 2021 /PRNewswire/ -- The corona pandemic continues to pose a global threat: To date, it has been possible to vaccinate only a small fraction of the total population. On top of that, there is acute danger from mutations of this virus. Against this backdrop, the DG-...

2021-03-11 08:00 1444

Sofwave Receives Australian Regulatory Approval to Market SUPERB™, the Breakthrough Ultrasound Technology Treating Fine Lines & Wrinkles

It is time to position your aesthetic practice at the forefront of innovation! YOQNEAM, Israel, March 10, 2021 /PRNewswire/ -- Sofwave Medical, the emerging leader of energy-based non-invasive, skin treatment aesthetic medical devices, announced today that it received approval fromAustralia's The...

2021-03-10 23:32 1537

Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S.

SHANGHAI, March 10, 2021 /PRNewswire/ -- Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 inthe United States. This is a Phase 1, open-label, multi-center, dose escalation and expansion study to e...

2021-03-10 21:14 1902

Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization

SHANGHAI, March 9, 2021 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases, today announced the completion of overUS$100 million Series B financing. The Series B round was led by Loyal Valley Capital...

2021-03-10 08:00 2299

Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients

* ALA-1000 is the first, three-month slow-release Buprenorphine injection. * Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. * ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treat...

2021-03-10 00:00 1768

Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.

SUZHOU, China, March 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate an open label, multi-center phase II pivotal clinical study (clinical trial ...

2021-03-09 20:00 3887

Nippon Express (Malaysia) Obtains GDP Certification for Domestic Transport Services

TOKYO, March 9, 2021 /PRNewswire/ -- Nippon Express (Malaysia) Sdn, Bhd. (hereinafter, "NE Malaysia"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has obtained Good Distribution Practice (GDP) certification effectiveThursday, January 14, 2021 for its Kuala Lumpur International A...

2021-03-09 15:00 1865

Yangtze River Pharmaceutical (Group) Co., Ltd. Won the 2021 EFQM Global Award

TAIZHOU, China, March 8, 2021 /PRNewswire/ -- At 19:20 on March 4, 2021 (Beijing time), the results of the 2021 EFQM Global Award were announced. Yangtze River Pharmaceutical (Group) Co., Ltd. fromChina was on the list, which represents that its quality management level has been aligned with that...

2021-03-09 11:19 1797

Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in China

HANG ZHOU, China, March 8, 2021 /PRNewswire/ -- On Feb. 26th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as "Winhealth Pharma") signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as "Merz"). The strategic cooperation betwe...

2021-03-09 10:00 3590

VolitionRx Limited to Present at Conferences in March 2021

AUSTIN, Texas, March 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer,Cameron Reynolds, and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at six conferences inMarch 2021. Duri...

2021-03-09 05:15 6259

Two-sided fitness marketplace Onekeelo launches, connecting consumers with personal trainers from all around the world at any time of the day

MELBOURNE, Australia, March 8, 2021 /PRNewswire/ -- Today, Onekeelo , the fitness marketplace that connects personal trainers and body transformation specialists with exercise enthusiasts has globally launched. This new online platform is innovating the way people select t...

2021-03-09 05:00 1707

Origin Agritech Ltd Utilized Gene Editing Technology to Create New Corn Traits

BEIJING, March 8, 2021 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, today announced that it has successfully utilized gene editing technology to create new corn traits. Gene editing refers to editing DNA strands by introducing...

2021-03-08 22:00 7473

CMAB Biopharma Congratulates Partner Junshi Biosciences on NMPA Acceptance of Application for a Clinical Trial of its PD-1/TGF-β Bifunctional Fusion Protein

SUZHOU, China, March 7, 2021 /PRNewswire/ -- Recently, CMAB Biopharma (Suzhou) Inc's ("CMAB") partner Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences") (HK: 1877; SH: 688180), announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (J...

2021-03-08 11:41 1989
1 ... 299300301302303304305 ... 313

Week's Top Stories